Inovio Pharmaceuticals (NASDAQ:INO) Stock Keeps Buy Rating at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $5.00 target price on the biopharmaceutical company’s stock. HC Wainwright‘s price objective suggests a potential upside of 238.98% from the company’s current price.

A number of other research analysts have also recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Inovio Pharmaceuticals in a research note on Wednesday. Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Piper Sandler reiterated an “overweight” rating and issued a $6.00 price objective (down from $8.00) on shares of Inovio Pharmaceuticals in a report on Wednesday. Zacks Research downgraded Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 12th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $8.00 price objective (up from $3.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 6th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.33.

Inovio Pharmaceuticals Stock Performance

Shares of INO opened at $1.48 on Thursday. Inovio Pharmaceuticals has a one year low of $0.56 and a one year high of $2.72. The company has a 50-day simple moving average of $1.18 and a two-hundred day simple moving average of $1.27.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.29). The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $2.27 million. As a group, equities research analysts predict that Inovio Pharmaceuticals will post -0.74 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in INO. HighTower Advisors LLC raised its stake in Inovio Pharmaceuticals by 104.8% during the third quarter. HighTower Advisors LLC now owns 26,076 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 13,346 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter worth $33,000. Engineers Gate Manager LP bought a new position in shares of Inovio Pharmaceuticals during the second quarter valued at $37,000. Squarepoint Ops LLC increased its holdings in shares of Inovio Pharmaceuticals by 46.5% during the second quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 11,554 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC raised its position in shares of Inovio Pharmaceuticals by 312.4% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 53,510 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.